亚临床心脏适应不良与PCP-HF心衰风险评分的关联
该横断面研究纳入1020名无心血管疾病的社区人群,评估PCP-HF十年心衰风险评分与超声心动图亚临床心脏重构/功能异常的一致性。结果显示风险评分越高,左室重构和功能障碍患病率越高,评分对左室舒张功能异常的检测准确率达87%。PCP-HF评分能有效识别心衰症状出现前的亚临床心脏适应不良个体。
要点
- PCP-HF评分可识别心衰症状前的亚临床心脏适应不良。
- 十年心衰风险评分加倍与左室舒张功能异常风险显著相关(OR 2.28)。
- 年龄、体重指数和收缩压是超声异常的关键相关因素。
核心结论
- PCP-HF风险评分能充分检测出心衰症状出现前数年的亚临床心脏适应不良个体。
- 该评分可能作为一级预防中有价值的心衰预测工具。
研究设计与样本
- 横断面分析,纳入Flemish环境、基因与健康结局研究中2005年5月至2015年1月接受临床检查包括超声心动图的参与者。
- 排除年龄小于30岁或大于79岁、存在现患心血管疾病和/或超声成像质量欠佳者,最终分析1020人(平均年龄52.8岁,女性541人占53.0%)。
主要发现
- 左室重构和功能障碍的患病率从低到中、高十年心衰风险评分组显著升高。
- 十年心衰风险评分加倍与左室向心性重构(OR 1.48,95%CI 1.36-1.61,P<.001)、左室肥厚(OR 1.66,95%CI 1.51-1.83,P<.001)、左室纵向应变异常(OR 1.12,95%CI 1.05-1.19,P<.001)和左室舒张功能障碍(OR 2.28,95%CI 1.94-2.69,P<.001)的 odds 升高相关。
- PCP-HF评分检测超声异常的准确率分别为:左室向心性重构74%、左室肥厚78%、左室纵向应变异常59%、左室舒张功能障碍87%。
- 高十年心衰风险评分者发生左室向心性重构、肥厚和舒张功能障碍的可能性分别是平均人群风险的3.1、3.8和9.4倍(P<.001)。
- 多变量校正分析中,年龄、体重指数和收缩压是超声异常的关键相关因素。
关键数值与推荐
- 基于三分位数界限,将参与者分为低(≤0.4%)、中(0.4%-2.4%)、高(≥2.4%)十年心衰风险评分组。
临床怎么用
- 在初级预防中,可使用PCP-HF评分从常规临床数据计算十年心衰风险,辅助识别可能需要进一步超声评估的亚临床心脏适应不良个体。
局限性
- 横断面设计无法确定因果关系。
- 研究人群为特定社区队列,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The Pooled Cohort Equations to Prevent Heart Failure (PCP-HF) estimate the 10-year risk for symptomatic heart failure (HF) from routine clinical data. The PCP-HF score should detect asymptomatic individuals with cardiac maladaptation preceding HF symptoms for it to be a useful HF prediction tool in primary prevention. OBJECTIVE: To assess the concordance between PCP-HF risk scoring and the presence of subclinical cardiac maladaptation in the community. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis included participants enrolled in the Flemish Study on Environment, Genes and Health Outcomes who underwent a clinical examination including echocardiography between May 2005 and January 2015. Participants younger than 30 years, older than 79 years, had prevalent cardiovascular disease, and/or had suboptimal echocardiographic imaging quality were excluded. Analysis began February 2020 and ended April 2020. EXPOSURES: Ten-year HF risk as calculated from routine clinical data using the PCP-HF. Based on tertile limits, participants were categorized as having low (≤0.4%), intermediate (0.4%-2.4%), and high (≥2.4%) 10-year HF risk score. MAIN OUTCOMES AND MEASURES: Echocardiographic profiles of subclinical heart remodeling and dysfunction. RESULTS: A total of 1020 individuals were analyzed (mean [SD] age, 52.8 [11.4] years; 541 female [53.0%]). The prevalence of left ventricular (LV) remodeling and dysfunction was significantly higher from low to intermediate and high 10-year HF risk score. A doubling in 10-year HF risk score was associated with higher odds for LV concentric remodeling (odds ratio [OR], 1.48; 95% CI, 1.36-1.61; P < .001), LV hypertrophy (OR, 1.66; 95% CI, 1.51-1.83; P < .001), abnormal LV longitudinal strain (OR, 1.12; 95% CI, 1.05-1.19; P < .001), and LV diastolic dysfunction (OR, 2.28; 95% CI, 1.94-2.69; P < .001). Moreover, the PCP-HF score detected echocardiographic abnormalities with an accuracy of 74% (LV concentric remodeling), 78% (LV hypertrophy), 59% (abnormal LV longitudinal strain), and 87% (LV diastolic dysfunction). The likelihood of LV concentric remodeling, hypertrophy, and diastolic dysfunction were 3.1, 3.8, and 9.4 times higher in participants with high 10-year HF risk score than the average population risk, respectively (P < .001). Of all PCP-HF score components, age, body mass index, and systolic blood pressure were key correlates of echocardiographic abnormalities in multivariable-adjusted analysis. CONCLUSIONS AND RELEVANCE: PCP-HF risk scoring adequately detected individuals with subclinical heart maladaptation that precedes HF symptoms by years. Thus, it may be a valuable HF prediction tool in primary prevention.
引用
- Cauwenberghs N, Haddad F, Kuznetsova T, et al. Association of Subclinical Heart Maladaptation With the Pooled Cohort Equations to Prevent Heart Failure Risk Score for Incident Heart Failure. JAMA Cardiol. 2021. PMID: 33175083. doi:10.1001/jamacardio.2020.5599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。